Showing results (81-90 of 90) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 90 results.
Iscience|January 15, 2026
Erratum: Site-specific ERα phosphorylation determines sex-dependent metabolic, reproductive, and body-compositional phenotypes in miceBinghao Zou, Jarvis Williams, Madeleine B Landau, et al.
Journal of Thoracic Imaging|July 13, 2015
Imaging Tumor Response and Tumoral Heterogeneity in Non-Small Cell Lung Cancer Treated With Antiangiogenic Therapy: Comparison of the Prognostic Ability of RECIST 1.1, an Alternate Method (Crabb), and Image Heterogeneity AnalysisConnie Yip, Nunzia Tacelli, Martine Remy-Jardin, et al.
Iscience|December 24, 2025
Site-specific ERα phosphorylation determines sex-dependent metabolic, reproductive, and body-compositional phenotypes in miceBinghao Zou, Jarvis Williams, Madeleine B Landau, et al.
Clinical Endocrinology|March 1, 2012
Temozolomide in the management of dopamine agonist-resistant prolactinomasB C Whitelaw, D Dworakowska, N W Thomas, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|October 3, 2008
Treatment of active Crohn's disease with MLN0002, a humanized antibody to the alpha4beta7 integrinBrian G Feagan, Gordon R Greenberg, Gary Wild, et al.
Cancers|June 27, 2024
Initial versus Staged Thyroidectomy for Differentiated Thyroid Cancer: A Retrospective Multi-Dimensional Cohort Analysis of Effectiveness and SafetyEman A Toraih, Mohammad H Hussein, Jessan A Jishu, et al.
Nature Communications|May 5, 2026
Rapid adaptive increase of amylase gene copy number in Indigenous AndeansKendra Scheer, Luane J B Landau, Kelsey Jorgensen, et al.
Oncogene|June 2, 2025
An FGFR-p53 developmental signaling axis drives salivary cancer progressionAdele M Musicant, Julia M R Billington, Jeffrey S Damrauer, et al.
International Journal of Radiation Oncology, Biology, Physics|December 7, 2019
Long-Term Results from the IDEAL-CRT Phase 1/2 Trial of Isotoxically Dose-Escalated Radiation Therapy and Concurrent Chemotherapy for Stage II/III Non-small Cell Lung CancerJohn D Fenwick, David B Landau, Angela T Baker, et al.
International Journal of Radiation Oncology, Biology, Physics|June 15, 2016
IDEAL-CRT: A Phase 1/2 Trial of Isotoxic Dose-Escalated Radiation Therapy and Concurrent Chemotherapy in Patients With Stage II/III Non-Small Cell Lung CancerDavid B Landau, Laura Hughes, Angela Baker, et al.
Pageof 9